Is there something wrong in paradise? Christian beliefs and the safety of novel BCR/ABL1 inhibitors

Documenti analoghi

• BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib
  di: Byrgazov, Konstantin, et al.
  Pubblicazione: (2018)
• Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities
  di: Valent, Peter
  Pubblicazione: (2011)
• Comment on “Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors”
  di: Kim, Sung-Hyun, et al.
  Pubblicazione: (2015)
• AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
  di: Weisberg, E, et al.
  Pubblicazione: (2006)
• The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
  di: Hantschel, Oliver, et al.
  Pubblicazione: (2007)